ITNS Stock Overview

A development stage company, focuses on producing and marketing over the counter and prescription homeopathic preparations to treat common ailments and chronic diseases. More details

ITNS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($762K)

Latest financial reports are more than a year old

Highly volatile share price over the past 3 months compared to the US market

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Itonis, Inc. Competitors

AmeriCann

OTCPK:ACAN

US$683.0k

Altamira Therapeutics

OTCPK:CYTO.F

US$452.2k

Universe Pharmaceuticals

NasdaqCM:UPC

US$407.8k

CBD Life Sciences

OTCPK:CBDL

US$1.5m

Price History & Performance

Summary of share price highs, lows and changes for Itonis
Historical stock prices
Current Share Price	US$0.0005
52 Week High	US$0.0013
52 Week Low	US$0.00019
Beta	0
1 Month Change	0%
3 Month Change	0%
1 Year Change	-9.09%
3 Year Change	-72.22%
5 Year Change	-50.00%
Change since IPO	-99.71%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ITNS	US Pharmaceuticals	US Market
7D	25.0%	0.1%	-0.5%
1Y	-9.1%	0.6%	21.1%

Return vs Industry: ITNS underperformed the US Pharmaceuticals industry which returned 1.4% over the past year.

Return vs Market: ITNS underperformed the US Market which returned 23.1% over the past year.

Price Volatility

Is ITNS's price volatile compared to industry and market?
ITNS volatility
ITNS Average Weekly Movement	40.9%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	5.9%
10% most volatile stocks in US Market	18.2%
10% least volatile stocks in US Market	3.0%

Stable Share Price: ITNS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ITNS's weekly volatility has decreased from 49% to 41% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2005	n/a	Mark Cheung	www.itonisholdings.com

Itonis, Inc., a development stage company, focuses on producing and marketing over the counter and prescription homeopathic preparations to treat common ailments and chronic diseases. The company intends to sells its over-the-counter to alleviate mild to moderate nausea. It has placed a manufacturing order for the first batch of its Emesyl product line.

Itonis, Inc. Fundamentals Summary

How do Itonis's earnings and revenue compare to its market cap?
ITNS fundamental statistics
Market cap	US$761.70k
Earnings (TTM)	-US$1.39m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ITNS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ITNS income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$1.39m
Earnings	-US$1.39m

Last Reported Earnings

Nov 30, 2011

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did ITNS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/12 19:13
End of Day Share Price	2025/02/12 00:00
Earnings	2011/11/30
Annual Earnings	2011/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Itonis, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.